---
title: "Avricore’s HealthTab Strikes Multi-Year UK Point-of-Care Testing Deal with Abbott"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299305366.md"
description: "Avricore Health's subsidiary, HealthTab, signed a multi-year agreement with Abbott to supply and distribute point-of-care testing products in UK community pharmacies. The deal focuses on deploying the Afinion 2 analyzer for HbA1c and lipid profile testing within NHS-linked pharmacies, supported by HealthTab's cloud platform for data integration. Meanwhile, TipRanks' AI analyst rates AVCR stock as Neutral due to deteriorating financial performance, despite a low-debt balance sheet."
datetime: "2026-09-17T10:34:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299305366.md)
  - [en](https://longbridge.com/en/news/299305366.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299305366.md)
generator: "portal-rs"
---

# Avricore’s HealthTab Strikes Multi-Year UK Point-of-Care Testing Deal with Abbott

Avricore Health ( (TSE:AVCR) ) has shared an announcement.

On August 20, 2026, Avricore’s HealthTab subsidiary signed a multi-year collaboration agreement with global healthcare group Abbott to supply and distribute Abbott’s point-of-care testing products across UK community pharmacies. The deal initially centres on deploying the Afinion 2 analyzer in NHS-linked pharmacies for HbA1c and lipid profile testing, anchoring a structured framework for broader pharmacy-based point-of-care expansion in the country.

HealthTab’s secure cloud platform connects analyzers, patient results, quality-control data and pharmacist workflows to create a unified, scalable digital infrastructure for community testing. Supported by a rigorous quality management program run with CEQAL Inc., the network is designed to deliver lab-grade accuracy and real-time analytics, strengthening Avricore’s positioning in pharmacy-based diagnostics and potentially improving public-health reporting and patient care outcomes.

**Spark’s Take on AVCR Stock**

According to Spark, TipRanks’ AI Analyst, AVCR is a Neutral.

The score is held down primarily by deteriorating financial performance (very low TTM revenue, negative gross profit, widening losses, and negative operating/free cash flow), only partly offset by a low-debt balance sheet. Technical indicators are neutral-to-mildly positive, but valuation is hard to support with a negative P/E and no dividend data.

To see Spark’s full report on AVCR stock,  
 click here. 

**More about Avricore Health**

Avricore Health Inc. is a Canadian pharmacy service innovator focused on acquiring and developing early-stage technologies that enhance pharmacy practice and patient care. Through its wholly owned subsidiary HealthTab™, the company aims to build the world’s largest network of rapid point-of-care testing devices in community pharmacies, making actionable health information more accessible to patients and healthcare providers.

**Average Trading Volume:** 53,143

**Technical Sentiment Signal:** Sell

**Current Market Cap:** C$7.58M

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

- [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md)
- [Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall | ABT Stock News](https://longbridge.com/en/news/298942114.md)
- [What the West misses when it judges Chinaâs dogged AI pursuit](https://longbridge.com/en/news/300214004.md)
- [Amylyx Pharmaceuticals, Inc. $AMLX Shares Newly Purchased by Corient Private Wealth LP](https://longbridge.com/en/news/300213990.md)
- [Big AI's content problem: Take the work, keep the money](https://longbridge.com/en/news/300217405.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**